glp-1 and protein + Understanding GLP-1: What You Need

There are three GLP-1 FDA decisions expected in 2025, all for Novo Nordisks semaglutide: Ozempic for T2DM and peripheral artery disease (PAD) Wegovy SC for heart failure with preserved ejection fraction (HFpEF) and obesity The first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics talented team of clinical experts actively monitors this emerging landscape

Ultrapure berberine: at least 97% pure berberine hydrochloride

The Danish Patient Compensation Association has announced that it will compensate at least four patients who lost their vision after taking Wegovy and another GLP-1

It just feels thinner

What a realistic timeline looks like Weight loss on GLP1 medications is not linear

Limit ultra-processed and high-sugar meals to optimize results